





## The challenges of chronic wounds

### Highly exuding wounds are challenging to treat.

You may see exudate pooling, sloughy tissue and delayed healing due to the presence of biofilm. Open chronic wounds are at an **increased risk** of infection and can put additional demands on nurses' time and total healthcare costs.


Your patient's wellbeing will also be affected.
Their wound may be **painful** and they may feel **embarrassment** and **anxiety** from leakage.

It is not the environment you want to **see** for optimum wound healing, nor what your patients want to **feel**.



That is why we are looking at gelling fibres differently. Providing a wound healing solution that you want to **see** and that patients can **feel**.

A positive, shared experience for you and for them.



#### A gelling fibre which:



Transfers exudate efficiently\*1,2



Supports a clean wound bed<sup>3</sup>



Removes easily in one-piece<sup>3,4,5</sup>



Prevents biofilm reformation\*\*6,7

\*For Exufiber® Ag+ when exposed to a flow rate of 0.6ml/h at 40mmHg pressure for up to seven days8.

\*\* Exufiber Ag+ may be used as a part of a biofilm management approach as per international guidelines<sup>9</sup> (i.e. cleansing, debridement and reassessment).









# With next generation Hydrolock® technology



### What is Hydrolock® technology?

Unlike traditional gelling fibres, Exufiber® dressings are made from a non-woven material created from uniquely modified PVA\* fibres. These tightly packed fibres form a fibrous structure **able to transfer** exudate<sup>1,2</sup> and maintain integrity, even when saturated.



Hydrophilic fibres attract, absorb and lock-in high levels of exudate, transforming into a soft, conformable gel. This helps to break down slough by promoting autolytic debridement, supporting a clean wound bed<sup>3</sup>.

**Small spaces** between the fibres result in less free fluid within the dressing, supporting fluid retention, even under compression, reducing the risk of leakage and maceration<sup>3,4,5</sup>.

### **Stays intact**

The fibrous structure has a high wet integrity without the need for additional strengthening fibres and threads, minimising shedding and supporting one-piece removal<sup>3,4,5</sup>.



### Fluid transfer


Fluid is transferred both vertically and laterally, utilising the full absorption capacity of the dressing.

Even when wet, the fibrous structure remains intact, enabling capillary action to continuously and efficiently\*\* transfer fluid to a secondary dressing<sup>1,2</sup>.

### Locks in up to

more\*\*\* of the exudate absorbed than Aquacel® Extra<sup>TM 10</sup>.





<sup>\*</sup>Polyvinyl alcohol.

<sup>\*\*</sup>For Exufiber® Ag+ when exposed to a flow rate of 0.6ml/h at 40mmHg pressure for up to seven days8.

<sup>\*\*\*</sup>When comparing lab results for retention under pressure with Aquacel®, Aquacel® Extra™, Durafiber® and UrgoClean® dressings.



### See the transfer of exudate. Patients feel comfort.

When gelling fibres do not work in the way you would like, it impacts your patients. Leakage can mean periwound maceration and potentially, social embarrassment.

Exufiber® dressings efficiently\* transfer exudate from the wound bed<sup>1,2</sup> to the secondary dressing. They can be left in place for up to seven days\*\*, allowing undisturbed healing<sup>10,11</sup>.

You will see less pooling<sup>3,5</sup> and a more optimal environment for healing.

Meaning your patients may feel more comfortable and confident.



#### **Proven transfer ability**

Using a cavity model to simulate fluid transfer capability, Exufiber® demonstrated **better fluid transfer capability** than Aquacel®, leaving less fluid in the cavity when the dressing was removed.

\*For Exufiber® Ag+ when exposed to a flow rate of 0.6ml/h at 40mmHg pressure for up to seven days8.

98%

#### of clinicians

Reported patient comfort as 'good' or 'very good' for Exufiber® 4.

Rated Exufiber® as 'easy' or 'very easy' to remove in one-piece 4.



### See one-piece removal. Patients feel relieved.


Traditional gelling fibres can leave debris and residue in the wound. This can trigger a foreign body response and disturb healing<sup>12</sup>, leading to patient discomfort, infection and trauma.

Exufiber® stays intact during use<sup>4</sup> and removes cleanly and easily in one-piece<sup>3,5</sup> so that **you can see a wound bed without dressing residue** or debris.

Your patients feel relief that dressing changes may be quicker and less stressful.







<sup>\*\*</sup>Exufiber® and Exufiber® Ag+ can be left in place for up to seven days depending on wound condition and clinical practice. In addition, Exufiber® can be left in place for up to 14 days on donor sites.






### See a cleaner wound bed. Patients feel less anxious.

Highly exuding wounds can often be sloughy, delaying healing and requiring mechanical debridement which may cause patients additional distress. Exufiber® promotes autolytic debridement, helping to break down slough<sup>5</sup>, and reducing the need for further intervention.

You will see a wound bed ready for healing and your patients may feel less pain and anxiety at dressing change.




### See wound progression. Patients feel reassured.

With biofilm present in almost all chronic, non-healing wounds<sup>9</sup>, it is important you have solutions to address this challenge.

Exufiber® Ag+ is proven to reduce biofilm bacteria and **prevent** reformation in vivo\*6,7.

This means you can see a wound heading in the right direction.

Your patients feel reassured their wound is being supported to heal.




### \*As part of a holistic biofilm management approach as per international guidelines (i.e. cleansing, debridement and reassessment).

#### **Broad-range antimicrobial effect**

Exufiber® Ag+ contains fine silver sulphate crystals. These dissolve on contact with exudate, releasing silver ions, which are proven to kill a broad range of pathogens<sup>13,14,15</sup>.

The antimicrobial effect is rapid (from three hours, *in vitro*) and has a sustained effect (up to seven days, *in vitro*)<sup>13,14,15</sup>.



### Backed by clinical evidence

### **Outperforms competition**

**Randomised Controlled Trial** 

A recent Randomised Controlled Trial<sup>16</sup> of 248 venous leg ulcer patients found that Exufiber® outperformed Aquacel® Extra<sup>TM</sup> across multiple measures:



A positive trend for **better wound size reduction** 



Clinician satisfaction for overall experience of use, ease of removal, and non-adherence to the wound bed



Clinicians reported **better absorption** and lock-in of exudate, blood and slough

### The Exufiber® Effect

### **Patient case study**

An elderly patient presented with a large, heavily exuding wound on her heel and calcaneus, with approximately 50% sloughy tissue. Initially, Exufiber® Ag+ was used as the primary dressing to help manage the bioburden and high exudate levels. After two weeks, treatment continued with Exufiber® to manage exudate levels while assisting autolytic debridement. Following eight weeks of therapy, the wound had a 50% area reduction, was moving in a positive trajectory and had no clinical signs of infection.



After 8 weeks

**Baseline** 


Photographs and case notes kindly supplied by Dr. Paulo Alves, Catholic University of Portugal, Porto, Portugal





# Discover how The Exufiber® Effect can make a difference to you and your patients at molnlycke.com

The difference you can see.




The difference they can feel.



### The perfect combination

Mepilex® Border Flex is the recommended secondary dressing for Exufiber® and Exufiber® Ag+. It combines innovative Flex Technology with our proven Safetac® technology, for a secondary dressing that stays on and uniquely conforms.



References: 1. Mölnlycke Health Care. Data on file. (2018). 2. Mölnlycke Health Care. Data on file. (2020). 3. Chadwick P, McCardle J. Open, non-comparative, multicenter post clinical study of the performance and safety of a gelling fibre wound dressing on diabetic foot ulcers. Journal of Wound Care, 25(4): 290-300 (2016). 4. Davies P, McCarty S. An in-use product evaluation of a gelling fibre dressing in wound management. E-poster presentation at Wounds UK Conference, 2017, Harrogate, United Kingdom. 5. Smet S, Beele H, Saine L, Suys E, Henrickx B. Open, noncomparative, multicentre post market clinician follow-up investigation to evaluate performance and safety on pressure ulcers when using a gelling fibre dressing as intended. Poster Presentation at European Pressure Ulcer Advisory Panel Conference, 2015, Ghent, Belgium. 6. Gil et al. Evaluation of a Gelling fiber dressing with silver to eliminate MRSA biofilm infections and enhance the healing. Poster presented at the Symposium on Advanced Wound Care Spring Meeting/Wound Healing Society (WHS) Annual Meeting 2017, Apr 05 - 09, 2017, San Diego, CA, USA. 7. Davis S C, Li J, Gil J. Head C, Valdes J, Glinos G D, Solis M, Higa A, Pastar I. Preclinical evaluation of a novel silver gelling fiber dressing on Pseudomonas aeruginosa in a porcine wound infection model. Wound Rep Reg, 27: 360-365 (2019). 8. Mölnlycke Health Care. Exufiber® Ag+: Physical properties over time. Data on file. (2019). 9. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm Made Easy. London: Wounds International 2017. 10. Surgical Material Testing Laboratory BS EN 13726-1:2002: Test methods for primary wound dressings. Mölnlycke Health Care. Data on file. (2014). 11. Mölnlycke Health Care. Data on file. (2014). 12. McGrath A. Overcoming the challenge of overgranulation. Wounds UK 7(1): 42–9 (2011). 13. Mölnlycke Health Care. CE: Performance of Exufiber® Ag+ in vitro; Antimicrobial effect, silver release kinetics and minimal effective concentration. Data on file. 2016. 14. Hamberg K, Gerner E, Falkbring S. Antimicrobial effect of a new silver-containing gelling fibre dressing against common wound pathogens. Poster presented at the Symposium on Advanced Wound Care Spring Meeting/Wound Healing Society (WHS) Annual Meeting, Apr 05 - 09, 2017, San Diego, CA, USA. 15. Hamberg K, Gerner E, Falkbring S. In vitro evaluation of the antimicrobial effect of silver-containing fibre dressings. Poster presented at the Symposium on Advanced Wound Care Spring Meeting/Wound Healing Society (WHS) Annual Meeting, Apr 05 – 09, 2017, San Diego, CA, USA. 16. Joergensen B, Blaise S, Svensson A-S. A randomised, open-label, parallel-group, multicentre, comparative study to compare the efficacy and safety of Exufiber® with Aquacel® Extra™ dressings in exuding venous and mixed aetiology leg ulcers. Int Wound J. 2022; 19(S1): 22-38. doi: https://doi.org/10.1111/iwj.13913.

	number	(cm)	RET	TRP
Exufiber®	709900	5 x 5	10	40
	709901	10 x 10	10	80
	709903	15 x 15	10	60
	709905	4.5 x 10	10	40
	709906	4.5 x 20	10	50
	709907	4.5 x 30	10	60
	709904	20 x 30	5	25
	709908	1 x 45	5	25
	709909	2 x 45	5	25
Exufiber® Ag+	603401	5 x 5	10	40
	603402	10 x 10	10	60
	603403	15 x 15	10	60
	603404	4.5 x 10	10	40
	603405	4.5 x 20	10	50
	603406	4.5 x 30	10	60
	603407	20 x 30	5	20
	603400	2 x 45	5	20

Size

Pcs

Pcs

**Ordering** 

Mölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00. The Mölnlycke, Exufiber, Hydrolock, Mepilex and Safetac trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care Group of Companies. ©2023 Mölnlycke Health Care AB. All rights reserved HQIM004181. Aquacel and Aquacel Ag Extra are registered trademarks of ConvaTec Inc.

Durafiber is a registered trademark of Smith & Nephew. UrgoClean is a registered trademark of Urgo Medical.